Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.
AUTOR(ES)
Kato, M
RESUMO
The in vitro and in vivo activities of Sm-1652 were compared with those of other cephalosporins. SM-1652 possessed a wide antibacterial spectrum which included activity against Pseudomonas aeruginosa. It also exhibited potent antibacterial activities against gram-positive cocci and clinical isolates of glucose nonfermentative bacteria. Most notably, its activity against glucose nonfermentative bacteria was the highest of all of the drugs tested. The bactericidal activity of SM-1652 was compared with that of cefoperazone. The difference between the minimum bactericidal concentration and the minimum inhibitory concentration of SM-1652 was actually smaller than that of cefoperazone for Escherichia coli and clinical isolates of indole-positive Proteus spp. SM-1652 was stable for most cephalosporinases but was hydrolyzed to some extent by penicillinases. The in vivo therapeutic effect of SM-1652 against infections in mice was better than those of cefazolin and cefoxitin. The in vivo antipseudomonal activity of SM-1652 was second to that of cefsulodin.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=185652Documentos Relacionados
- In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity.
- Evolution of plasmid-coded resistance to broad-spectrum cephalosporins.
- Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.
- Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.
- Novel plasmid-mediated beta-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins.
